FUJIFILM Diosynth Biotechnologies - June 2024

Jacobs Selected to Support Delivery of $1.2B Expansion of our Holly Springs, North Carolina Site

We are proud to continue our partnership with Jacobs as together, we work towards the completion of one of the largest, end-to-end cell culture contract manufacturing facilities in North America. Read more.

Reflecting on BIO 2024?

We want to extend our thanks to all who participated, organized, and joined us at #BIO2024 this month! It was a remarkable event with some amazing discussions had and partnerships forged with the inspiring ambition of furthering tomorrow's life-changing medicines. Here’s a snapshot of what we got up to at this year’s conference.??

If you missed us at BIO but would like to discuss your project, feel free to contact us.?

Partnering with SCHOTT Pharma to Share Insights on Drug Product Manufacturing

On June 13 we were honored to host 79 guests from 33 pharmaceutical companies at our site in Hiller?d, Denmark, where we focused on exploring ways to achieve successful outcomes in drug product manufacturing. Our guests gained valuable insights into drug product and finished goods processes and best practices from subject matter experts at both FUJIFILM Diosynth Biotechnologies and SCHOTT Pharma. They also enjoyed the opportunity to network with fellow industry experts and to take a tour of our facility, featuring our state-of-the-art filling line. Thank you all for joining us and for contributing your insights.

???

A Look Inside Fujifilm’s Innovation Hub?

Fujifilm’s Advanced Research Laboratories, situated in Kaisei, Japan, is an innovation hub and core research and development institute. In this article, we highlight two projects that exemplify the scope and diversity of our ongoing research and technical innovations in Kaisei. The overarching theme across these projects is a focus on improving efficiency and productivity in biopharmaceutical manufacturing while also reducing the cost of goods through process intensification.?

?

Extracellular Vesicles (EV): Building the Next Therapeutic Modality with End-to-End Product and Service Support?

In order to further the development of EV applications, Fujifilm Life Sciences is leveraging its expertise across four of its Life Sciences companies to provide the full range of products and services required for the development and manufacture of EV therapeutics. Learn more about Fujifilm EV Total Solutions and the end-to-end support we provide to researchers.??

Leveraging Advanced Analytical Capabilities to De-risk Drug Development

Characterizing a molecule's identity enables efficient process development and regulatory compliance. To achieve this, sponsors must leverage advanced analytical techniques that illuminate structure and purity. Learn more in this article?by Jason Barker, Director of Analytical Development, Analytical Methods Transfer and Formulation Development at FDB.

?

?